Nemonoxacin is a non-fluorinated quinolone antibiotic undergoing clinical trials.

At the end of 2016, it had reached market in Taiwan, Russia, the Commonwealth Independent States, Turkey, mainland China,[2] and Latin America[3] under the brand name Taigexyn.

[4] The U.S. Food and Drug Administration (FDA) has granted nemonoxacin qualified infectious disease product (QIDP) and fast track designations for community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin-structure infections (ABSSSI).

[6][7] However, it was less active against Gram-negative pathogens such as Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa, with MIC90 values of 32, 16, and 32 g/ml, respectively.

[8] The new drug also is effective against C.difficile isolates that are resistant to other quinolones,[9] and is more potent than levofloxacin or moxifloxacin.